PGF
Placenta growth factor
As of the edition of 20 October 2026, PGF (placenta growth factor, UniProt P49763) has 3 drugs tested at it and 10 companies on the list, 5 on route A and 3 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P49763
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Secreted
- Solved structures
- 2
- Disease areas
- Eye; Cancer; Heart and blood vessels; Hormones; Digestive system; Nervous system; Urinary and reproductive; Pregnancy and women's health
- Registered trials of its drugs
- 401
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Went quiet | 1 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Aflibercept | Marketed | Phase 4 | Ends 2030 |
| Conbercept | Marketed | Phase 4 | none listed |
| TB-403 | Went quiet | Phase 2 | none listed |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 5 |
| Route B | 3 |
| Undetermined | 2 |
| Total on the list | 10 |
| Company | Route |
|---|---|
| Amgen | Route B |
| Chengdu Kanghong Biotech | Route B |
| Bayer | Route B |
The other 7 companies at PGF
In the product10 companies in all; 7 are not named here, and no score is.
See the 10 companies at PGF, ranked, with the facts behind eachRequest access. Nothing is shown until you do.